Cargando…

Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden

BACKGROUND: Associations between different cancer types are known. The affirmation of the risk for non-ovarian cancer after ovarian borderline tumors (BOT) is, however, sparse. AIM: To analyze the risk of subsequent or simultaneous cancers in women with BOTs compared with the general female Swedish...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobilas, Arturas, Jansåker, Filip, Li, Xinjun, Sundquist, Kristina, Borgfeldt, Christer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561436/
https://www.ncbi.nlm.nih.gov/pubmed/37807065
http://dx.doi.org/10.1186/s12885-023-11453-6
_version_ 1785117922742501376
author Dobilas, Arturas
Jansåker, Filip
Li, Xinjun
Sundquist, Kristina
Borgfeldt, Christer
author_facet Dobilas, Arturas
Jansåker, Filip
Li, Xinjun
Sundquist, Kristina
Borgfeldt, Christer
author_sort Dobilas, Arturas
collection PubMed
description BACKGROUND: Associations between different cancer types are known. The affirmation of the risk for non-ovarian cancer after ovarian borderline tumors (BOT) is, however, sparse. AIM: To analyze the risk of subsequent or simultaneous cancers in women with BOTs compared with the general female Swedish population. METHODS: An open cohort study (1995–2018) was conducted where a diagnosis of BOTs as well as subsequent or simultaneous cancer diagnoses were obtained from the Swedish Cancer Register and matched to the Total Population Register. Each woman with BOT was followed until non-ovarian cancer, death or emigration and could only be included once for the outcome. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) for specific non-ovarian cancers were analyzed. RESULTS: The 4998 women with serous and mucinous BOTs were diagnosed during 1995–2018 with a mean age of 55.7 years (SD 16.0) at diagnosis. Compared with the general female population, women with BOTs had increased risks for non-ovarian cancer in colon (SIR = 2.5; 95% CI 2.0–3.1), rectum (SIR = 1.7; 95% CI 1.1–2.5), small intestine (SIR = 5.0; 95% CI 2.3–9.5), cervix (SIR = 2.5; 95% CI 1.4–4.2), endometrium (SIR = 2.4; 95% CI 1.9–3.1), pancreas (SIR = 2.3; 95% CI 1.4–3.5), upper aerodigestive tract (SIR = 2.2; 95% CI 1.2–3.8), lung (SIR = 1.8; 95% CI 1.4–2.3), kidney (SIR = 2.3; 95% CI 1.4–3.7) and bladder (SIR = 1.8; 95% CI 1.1–2.8). Among women with serous BOTs, the risk of thyroid gland cancer (SIR = 3.1; 95% CI 1.2–6.4) was also increased. Lung and pancreas cancer showed increased risks more than 1 year after a diagnosis of BOT. CONCLUSIONS: This Swedish population-based study demonstrated an increased risk of multiple malignancies including lung and pancreatic cancers beyond the first year of diagnosis in patients with borderline ovarian tumors (BOTs), suggesting a potential shared etiology. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11453-6.
format Online
Article
Text
id pubmed-10561436
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105614362023-10-10 Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden Dobilas, Arturas Jansåker, Filip Li, Xinjun Sundquist, Kristina Borgfeldt, Christer BMC Cancer Research BACKGROUND: Associations between different cancer types are known. The affirmation of the risk for non-ovarian cancer after ovarian borderline tumors (BOT) is, however, sparse. AIM: To analyze the risk of subsequent or simultaneous cancers in women with BOTs compared with the general female Swedish population. METHODS: An open cohort study (1995–2018) was conducted where a diagnosis of BOTs as well as subsequent or simultaneous cancer diagnoses were obtained from the Swedish Cancer Register and matched to the Total Population Register. Each woman with BOT was followed until non-ovarian cancer, death or emigration and could only be included once for the outcome. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) for specific non-ovarian cancers were analyzed. RESULTS: The 4998 women with serous and mucinous BOTs were diagnosed during 1995–2018 with a mean age of 55.7 years (SD 16.0) at diagnosis. Compared with the general female population, women with BOTs had increased risks for non-ovarian cancer in colon (SIR = 2.5; 95% CI 2.0–3.1), rectum (SIR = 1.7; 95% CI 1.1–2.5), small intestine (SIR = 5.0; 95% CI 2.3–9.5), cervix (SIR = 2.5; 95% CI 1.4–4.2), endometrium (SIR = 2.4; 95% CI 1.9–3.1), pancreas (SIR = 2.3; 95% CI 1.4–3.5), upper aerodigestive tract (SIR = 2.2; 95% CI 1.2–3.8), lung (SIR = 1.8; 95% CI 1.4–2.3), kidney (SIR = 2.3; 95% CI 1.4–3.7) and bladder (SIR = 1.8; 95% CI 1.1–2.8). Among women with serous BOTs, the risk of thyroid gland cancer (SIR = 3.1; 95% CI 1.2–6.4) was also increased. Lung and pancreas cancer showed increased risks more than 1 year after a diagnosis of BOT. CONCLUSIONS: This Swedish population-based study demonstrated an increased risk of multiple malignancies including lung and pancreatic cancers beyond the first year of diagnosis in patients with borderline ovarian tumors (BOTs), suggesting a potential shared etiology. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11453-6. BioMed Central 2023-10-09 /pmc/articles/PMC10561436/ /pubmed/37807065 http://dx.doi.org/10.1186/s12885-023-11453-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Dobilas, Arturas
Jansåker, Filip
Li, Xinjun
Sundquist, Kristina
Borgfeldt, Christer
Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden
title Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden
title_full Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden
title_fullStr Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden
title_full_unstemmed Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden
title_short Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden
title_sort risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in sweden
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561436/
https://www.ncbi.nlm.nih.gov/pubmed/37807065
http://dx.doi.org/10.1186/s12885-023-11453-6
work_keys_str_mv AT dobilasarturas risksofnonovariancancersinwomenwithborderlineovariantumoranationalcohortstudyinsweden
AT jansakerfilip risksofnonovariancancersinwomenwithborderlineovariantumoranationalcohortstudyinsweden
AT lixinjun risksofnonovariancancersinwomenwithborderlineovariantumoranationalcohortstudyinsweden
AT sundquistkristina risksofnonovariancancersinwomenwithborderlineovariantumoranationalcohortstudyinsweden
AT borgfeldtchrister risksofnonovariancancersinwomenwithborderlineovariantumoranationalcohortstudyinsweden